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Background: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontu-
berculous mycobacteria (NTM). Few data are available measuring the cost burden of
mycobacterial diseases at the national level. The purpose of this study is to evaluate the
cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM
cases in the United States from 2001 through 2012.
Methods: This study is a retrospective, community-based cost analysis of hospitalized
patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through
2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utiliza-
tion Project (HCUP), US Department of Health and Human Services. The statistical signifi-
cance of observed trends of NTM and TB national hospital costs was calculated using
Poisson log-linear regression.
Results: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pul-
monary TB in the US from 2001 through 2012. The total associated cost of these discharges
was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the
study period, the national hospital costs of pulmonary NTM increased at a statistically sig-
nificant rate in the US over each year (P = 0.001). However, no such increase was found for
national hospital costs of pulmonary TB.
Conclusions: The national hospital cost of NTM management is increasing. These results
emphasize the importance of continued research in pulmonary NTM in order to improve
current guidelines in prevention and treatment strategies.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.problem in the US and all over the world. TB incidence peaked
Introduction
Pulmonary mycobacterial diseases describe both tuberculosis
(TB) and nontuberculous mycobacteria (NTM). Pulmonarymycobacterial disease has been a long-term public health
in the early twentieth century in the US, when it became a
major cause of mortality [1].iversity of
, National
, Clinical
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resulted in a decrease in its incidence in recent years [2],
the incidence of NTM is increasing and has been classified
as an emerging public health problem in the US [3] and the
world [4,5]. The incidence of NTM has even surpassed that
of TB in several States of the US [6,7].
NTM are organisms that are found ubiquitously in the
environment. In the 1950s, NTM was first recognized as
human pathogens when 1–2% of various sanitarium’s
patients did not respond to routine anti-TB regimens [5,8].
Currently, over 150 NTM species are known, and many new
species with clinical relevance have recently been reported
[9].
Unlike TB, diseases caused by NTM generally have pro-
longed treatment for complete cure. Therefore, the preva-
lence is far greater than the incidence, and cost of
treatment is more dependent on prevalence than incidence.
Healthcare costs have been key factors in national econo-
mies, and controlling healthcare costs has become a priority
for essentially all countries in the world and is an important
area of research. Healthcare costs associatedwithmycobacte-
rial disease lie more heavily on public healthcare systems
because of the communicable nature of TB. The healthcare
costs of tuberculosis have been reported several times; the
average cost for hospitalization of non-drug-resistant TB
was estimated to be $28,000 per patient in 2005–2007 [10].
The hospital costs of managing patients with NTM disease
are less clear. A limited amount of data are available measur-
ing the healthcare costs of NTM at the national level.
Previously published studies have attempted to measure var-
ious aspects of cost, but have done so using small sample
sizes or with a limited study period [10–12]. The purpose of
this study is to offer a comprehensive evaluation of the in-
hospital costs of care for pulmonary TB and NTM using
national data during a long study period beginning in 2001
up through 2012.
Methods
Study design and patient data
This is a retrospective, population-based comparative study
using data obtained from the National Inpatient Sample
(NIS) within the Agency for Healthcare Research and
Quality’s Healthcare Cost and Utilization Project (HUCP). NIS
is the largest inpatient healthcare dataset in the US providing
national estimates of hospital costs stratified by disease State.
NIS collects data from every State participating in HCUP,Table 1 – The regions of the US were classified into four zones
Northeast Connecticut, Maine, Massachusetts, New Hampshi
Vermont
Midwest Illinois, Indiana, Iowa, Kansas, Minnesota, Missour
Wisconsin
South Alabama, Arkansas, Delaware, District of Columbia
Tennessee, North Carolina, Oklahoma, South Carol
West Alaska, Arizona, California, Colorado, Hawaii, Idah
Wyomingwhich represents more than 95% of the US population [13].
All patients with a principal diagnosis of pulmonary NTM
and TB whowere discharged from the hospital during the per-
iod 2001 through 2012 were included in this study.
Study definitions
Pulmonary NTM was defined by any hospital discharge asso-
ciated with a principal diagnosis of the International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9) code 031.0. This code includes pulmonary infection
by mycobacterium avium, mycobacterium intracellulare and
mycobacterium kansasii. Pulmonary TB was defined by any dis-
charge associated with ICD-9 codes 011.90–011.96. The princi-
pal diagnosis was defined as the main reason for discharge.
The regions of the US were classified into four zones recog-
nized by the Bureau of the Census as Northeast, Midwest,
South and West (Table 1). Length of stay was defined as the
number of nights the patient remained in the hospital.
Payer was defined by the type of insurance coverage carried
by the patient or lack thereof, which included Medicare,
Medicaid, private insurance (Blue Cross, commercial carriers,
and private HMOs and PPOs), uninsured (which includes an
insurance status of ‘‘self-pay’’ and ‘‘no charge’’), and other
(which includes Worker’s Compensation and other govern-
ment payers). Median income was defined as the median
household income of the patient’s zip code of residence and
compared with the national median income for the same
year. HCUPnet used value ranges of the median household
income itemized by year (Table 2) [14].
Study variables
Variables included in this study were age group, sex, region,
payer, median zip code, hospital length of stay in days, mean
hospital charge per discharge, mean aggregated charge, total
aggregated charge, and in-hospital deaths.
Statistical analysis
The statistical significance of observed trends of NTM and TB
national hospital costs were calculated using Poisson log-
linear regression. National hospital costs for NTM and TB
were projected in relation to healthcare inflation for each
year. Expected mean aggregated charge (EaC) was calculated
based on healthcare inflation using the equation:
(EaC = HCi · OaC), in which EaC is the expected aggregated
hospital charge, Hci is healthcare inflation percent for eachrecognized by the Bureau of the Census.
re, New Jersey, New York, Pennsylvania, Rhode Island, and
i, Michigan, Nebraska, North Dakota, Ohio, South Dakota and
, Florida, Georgia, Kentucky, Maryland, Mississippi, Louisiana,
ina, Texas, Virginia, and West Virginia
o, Montana, Nevada, New Mexico, Oregon, Utah, Washington,
Table 2 – Each year value ranges for calculation of median
income of patients’ ZIP code.
Year Low Not low
2003 $1–35,999 $36,000+
2004 $1–35,999 $36,000+
2005 $1–36,999 $37,000+
2006 $1–37,999 $38,000+
2007 $1–38,999 $39,000+
2008 $1–38,999 $39,000+
2009 $1–39,999 $40,000+
2010 $1–40,999 $41,000+
2011 $1–38,999 $39,000+
2012 $1–38,999 $39,000+
Adapted form: Ref. [14].
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divided by the total aggregated hospital charge for the prior
year · 100), and OaC is the observed aggregated charge for
each medical condition. A regression model was applied to
test the correlation between observed and projected aggre-
gated hospital charges, otherwise known as national hospital
costs. All statistical analyses were performed using SPSS sta-
tistical software (version 21.0, IBM Corporation).Table 3 – The demographic characteristics of patients with pulm
tuberculosis in the US from 2001 to 2012.
Variables
All discharges
Age group (%) <17
18–44
45–64
65–84
>85
Sex (%) Male
Female
Region (%) Northwest
Midwest
South
West
Payer (%) Medicare
Medicaid
Private ins
Uninsured
Other
Median income for zip code (%) Low
Not low
Missing
Length of stay per days (SD)
Mean hospital charge per discharge ($)
Mean aggregated charge ($)
Expected mean aggregated charge ($)
Total aggregated charge ($)
In-hospital deaths (mean/year)
Note: $: US dollar.Results
From a total of 36,484,846 discharges, 20,049 hospital dis-
charges were reported with pulmonary NTM and 44,370 with
pulmonary TB in the US from 2001 through 2012.
Age distribution varied between the two groups (Table 3).
The majority of pulmonary NTM patients were between 65–
84 years old (48.5%), while 70% of TB patients were younger
than 65. There was a significant difference between frequen-
cies of subjects more than 65 years old between the two
groups (P = 0.0001). There was a significant difference
between frequencies of the very elderly (+85) population
between the two groups (P < 0.00001, OR = 2.83). Pulmonary
NTM was 2.6 times higher in females than pulmonary TB
(P < 0.00001).
The incidence of pulmonary mycobacterial disease did not
vary between TB and NTM by geographical area. The south
region recorded the highest numbers of hospital discharges
for both in the US.
There was a significant difference in one payer status
between the TB and NTM group. Medicare paid 60% of pul-
monary NTM inpatient costs, but only 24% of the hospital
costs of subjects with pulmonary TB (P < 0.00001). There was
no difference in the other payer groups for NTM and TB.onary nontuberculous mycobacterial diseases and
NTM TB
20,049 44,370
1.8 5.1
7.6 36.3
31.3 33.8
48.5 20.7
10.8 4.1
44 67
56 33
19 21
16 13
43 43
22 23
61 24
10 23
urance 22 19
5 25
2 9
26 41
72 55
2 3
9.2 (0.5) 13.5 (1.5)
47,120 48,332
80,886,935 246,398,995
85,005,570 282,501,149
903,767,292 2,078,113,317
71 (0.35) 114 (0.26)
Fig. 2 – The trends of national hospital costs of pulmonary
nontuberculous mycobacterial disease in the US from 2001
to 2012.
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tus than patients with TB, based on zip code analysis. Only
26% of pulmonary NTM patients had a household income less
than their community, as compared with 41% for patients
with pulmonary TB (P = 0.0246, OR = 0.51). TB patients had a
longer hospital stay compared with NTM patients–TB averag-
ing 13 days vs. 9 days for NTM.
The total associated costs of a hospital stay for all condi-
tions during the study duration was $1,337,939,745,325, an
estimated $903,767,292 of which was directly associated with
pulmonary NTM and $2,078,113,317 with pulmonary TB. The
national hospital costs of pulmonary NTM increased at a sta-
tistically significant rate in the US over each year (P = 0.001)
(Fig. 1). A linear regression analysis demonstrated a high
degree of correlation between NTM observed and projected
national hospital costs (R = 0.938, P < 0.001) (Fig. 2). However,
no such correlation between observed and projected national
hospital costs was found for pulmonary TB (R = 0.284,
P = 0.372).
Discussion
This study showed that the cost burden for inpatient care of
patients with pulmonary mycobacterial diseases in the US
was around 3 billion dollars from 2001 through 2012. The
aggregated hospital charges for pulmonary NTM had an
increasing trend that was in the same trajectory with the
health care inflation. However, pulmonary TB inpatient costs
were not increasing at the same trend as the trajectory of
healthcare cost inflation.
A number of studies attempted to measure outpatient pul-
monary NTM-related costs. A small cohort study with 27 pul-
monary NTM subjects in a US-based center found an annual
antibiotic therapy cost of $5,196 for those infected with MAC
and $11,796 forMycobacterium abscessus [11]. Also emphasized
in this study, the NTM species was amajor factor in determin-
ing antibiotic cost. For instance M. abscessus was particularly
associated with higher treatment cost. Leber and Marras
studied 117 individuals with pulmonary NTM to determine
outpatient treatment costs in Canada [12]. They found that
the annual cost was $5,000 in Canadian currency and
antibiotics were responsible for 70% of the cost.Fig. 1 – The trends of observed and projected national
hospital costs of pulmonary nontuberculous mycobacterial
and tuberculosis disease in the US from 2001 to 2012.In this study, the hospital costs of pulmonary mycobacte-
rial disease were measured, but the full economic burden of
mycobacterial disease is impossible to measure. In addition
to the cost of delivering direct medical care in the inpatient
and outpatient setting, total cost involves many other finan-
cial and human costs, such as lost wages, travel expenses
and opportunity costs of the sick, the cost to administer pub-
lic health programs including surveillance and prevention,
and the economic impact on the family and social network
of those receiving care for the disease which may also include
lost wages, travel expenses and opportunity costs. This study
was only able to ascertain the inpatient costs.
Compared to patients with TB, patients with nontubercu-
lous mycobacteria were more often women. They were older
and came from areas with higher incomes, which has been
found in other studies [3,15,16]. In a population-based study,
it was recently shown that females die more frequently from
NTM, and the majority (78%) of NTM-related mortality occurs
in the patients 55 years of age or older [17]. This is particularly
important in the US, considering the aging of the baby
boomer population cohort (those born between the years
1945 and 1960), which has impacted population distribution
resulting in significantly more elderly people than young
and middle-aged in the US.
Adjemian and colleagues showed a relationship between
counties in the United States with a higher median household
income with the geographical distribution of pulmonary NTM
[18]. The data in the present study support their findings in a
population-based study.
The major limitation of this study was the use of ICD-9
codes. ICD-9 has limited codes for NTM, which includes only
the more common species M. avium complex and M. Kansasii.
With more than 150 currently reported species of NTM, this
cost assessment only included the most common NTM spe-
cies associated with pulmonary disease.
Conclusion
Pulmonary mycobacterial diseases are the source of an
immeasurable and significant economic burden. This study
supports previous data classifying NTM as an emerging dis-
ease with increasing incidence and cost. Also, the strong
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ing given the population structure of the US. As the large
number of baby boomers enter their final years, the incidence
of NTM is likely to demonstrate amplified increases, which
could have a profound impact on healthcare costs. More
research is needed to understand the total inpatient and out-
patient NTM costs and forecasting of future trends based on
disease surveillance relative to population distribution.
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